The Capital Fund has invested £250,000 as part of a £500,000 funding round in Biocontrol. Biocontrol's research focuses on developing the clinical use of bacteriophages, that is naturally occuring viruses, which attack and destroy harmful bacteria.
BCEP II follows a long-hold private equity strategy, with an investment period of 15 years
Combined companies will pursue a buy-and-build strategy, acquiring fitness studio chains
Marc Seeger joins the firm's Düsseldorf-based corporate and M&A team from Hengeler Mueller
GP acquires the automotive networked systems business as part of a succession solution